Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate
1. Valneva announces strong immune response from VLA15 booster doses. 2. No safety concerns were reported by independent monitoring committee. 3. VLA15 is the leading Lyme disease vaccine in clinical development. 4. Pfizer plans to submit regulatory applications in 2026 after Phase 3 trials. 5. Lyme disease affects 476,000 people annually in the U.S.